Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 16, 2024 09:00 ET | Source: Vivtex

Vivtex Enters New Research Agreement with Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy

Vivtex to apply its GI-ORIS™ technology to optimize oral bioavailability of EQ302, Equillium’s novel IL-15/IL-21 bi-specific peptide therapyEquillium targeting initiation of Phase 1 study...
June 03, 2021 08:00 ET | Source: Equillium

Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11

Presentation and conference call will include topline data from all cohorts The risk-benefit profile observed supports advancing development of itolizumab in first-line therapy LA JOLLA,...
May 13, 2021 08:00 ET | Source: Equillium

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association

LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
April 27, 2021 08:00 ET | Source: Equillium

Equillium Announces Three Abstracts Accepted for Presentation at the 104th Annual Meeting of the American Association of Immunologists

LA JOLLA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
March 15, 2021 08:00 ET | Source: Equillium

Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation

EQUATE acute graft-versus host disease (aGVHD) study observed rapid response and durability through day 85 EQUATE aGVHD study reported a clinically meaningful reduction in corticosteroid...
February 12, 2021 15:00 ET | Source: Equillium

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience

Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use Dose-dependent reduction of CD6 expression on CD4+ and CD8+ T cells is...
January 22, 2021 08:00 ET | Source: Equillium

Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital Experience

LA JOLLA, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
January 05, 2021 08:00 ET | Source: Equillium

Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference

LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
December 21, 2020 08:00 ET | Source: Equillium

Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of Research & Development and Chief Medical Officer

LA JOLLA, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
November 30, 2020 08:00 ET | Source: Equillium

Equillium to Host Virtual Investor and Analyst Day on December 4, 2020

Review positive interim data from the study of itolizumab for the treatment of acute GVHD and pipeline programs in lupus / lupus nephritis and uncontrolled asthma Featured guest speaker: John...

Next Page keyboard_arrow_right